The cancer-fighting tech disabling ‘force fields’ around tumours

ASX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement platform on stage at the prestigious CAR-TCR Summit in Boston.

ASX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement platform on stage at the prestigious CAR-TCR Summit in Boston.

As part of her presentation on ‘Enhancing persistence and efficacy of CAR-T therapies’ at the US conference last week, Senior VP of Scientific Affairs Dr Rebecca Lim revealed Prescient’s eagerly anticipated novel adjuvant/neoadjuvant, CellPryme-A.

The adjuvant therapy – which has been shown to boost the effectiveness and proliferation of CAR-T therapies, significantly improving tumour killing and survival – represents a leap forward for Prescient (ASX: PTX) in its mission to move cancer care from treatments towards personalised cures.

It is designed to be administered to cancer patients as an intravenous infusion to boost the effectiveness of cellular immunotherapy, such as CAR-T cell therapy, by overcoming the hostile tumour microenvironment that acts as a ‘force field’ for solid tumours.

CellPryme-A enhances tumour killing of conventional CAR-T cells and improves host survival by reducing suppressive Treg cells, increasing infiltration of CAR-T cells into solid tumours and dramatically increasing the ability of CAR-T cells to expand in vivo, the company said.

CEO and MD Steven Yatomi-Clarke said he was delighted that CellPryme-A – developed in collaboration with the Peter MacCallum Cancer Centre – expanded Prescient’s stable of cell therapy enhancements, noting it was “a distinct but complementary addition” to CellPryme-M.

Both platforms are also complementary with Prescient’s flagship OmniCAR platform, and can be incorporated into existing cell therapy programs as they enter clinical studies, opening up avenues for external collaborations and in-house applications, Mr Yatomi-Clarke said.

“Together with Prescient’s next-generation CAR platform, OmniCAR, Prescient has placed itself enviably at the forefront of cellular immunotherapy by creating technologies that overcome the challenges facing the field,” he said.

“These industry challenges – which include targeting an array of antigens, post infusion control, cell exhaustion and a suppressive tumour microenvironment – simply must be overcome in order to bring this promising new class of therapies to more patients, and to conquer different malignancies.

“We now have a comprehensive suite of technologies to address all of these challenges.”

Prescient Therapeutics CEO and MD Steven Yatomi-Clarke will be holding an investor briefing on Friday, 30th September, at 1pm (AEST) where he will provide an overview of the company’s deep pipeline. Click here to book in.

Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.

Past performance is not a reliable indicator of future performance.


This Week’s News


16 April 2024

Gold at record highs – so why aren’t gold stocks?


22 November 2023

Rare Earths Industry Review: Part 2


22 November 2023

Rare Earths Industry Review

General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG)

including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.